Impact of body mass lndex on locoregional control in saudi patients with breast cancer after breast conserving surgery and modified radical mastectomy

Alsaeed, Eyad; AlGhabbban, AbdulRahman Jameel; Tunio, Mutahir A.; Bayoumi, Yasser

doi:10.7243/2052-5966-2-1

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impact of BMI on survival outcomes has been studied in various malignancies such as breast and gastric cancers. 11 , 12 , 13 However, few studies have evaluated the BMI and obesity as a prognostic factor in head and neck malignancies. 14 Takenaka et al identified pretreatment BMI as an independent prognostic factor for survival among patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation, in their study the population was divided in to three groups: underweight (18.5 kg/m 2 < BMI),normal weight (18.5–25 kg/m 2 ) and overweight (25 kg/m 2 > BMI), and they noted that the overweight patients had the most favorable prognosis, and the underweight patients the worst.…”

Section: Discussionmentioning

confidence: 99%

Impact of body mass index on survival outcome in patients with differentiated thyroid cancer

Al-Ammar

Al-Mansour

Al-Rashood

et al. 2018

Brazilian Journal of Otorhinolaryngology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of body mass index on survival outcome in patients with differentiated thyroid cancer

Al-Ammar

Al-Mansour

Al-Rashood

et al. 2018

Brazilian Journal of Otorhinolaryngology

View full text Add to dashboard Cite

show abstract

“…A more recent study from Saudi Arabia that examined local recurrence in 112 women with non-metastatic breast cancer in relation to BMI does not offer any further corroboration. It found that patients with a BMI of 26–30 kg/m 2 had an increased likelihood of local-regional recurrence, but other ranges of BMI—including higher BMI—had no effect on the likelihood of local-regional recurrence (26). These patients underwent mastectomy with or without radiation (71%) or breast conservation therapy as local treatment.…”

Section: Discussionmentioning

confidence: 99%

Association of Locoregional Control With High Body Mass Index in Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer

Bergom

Kelly

Bedi

et al. 2016

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose Obesity, as measured by body mass index (BMI), is a risk factor for distant recurrence and decreased survival in breast cancer. We sought to determine whether BMI correlated with local recurrence and reduced survival in a cohort of predominantly obese women treated with breast conservation therapy. Methods and Materials From 1998–2010, 154 women with early stage invasive breast cancer and 39 patients with ductal carcinoma in situ (DCIS) underwent prone whole breast irradiation. Cox proportional hazards regression, Kaplan-Meier methods with log-rank test, and multivariate analysis were used to explore the association of outcomes with BMI. Results The median patient age was 60 years, and the median follow-up was 73 months. The median BMI was 33.2 kg/m2; 91% of patients were overweight (BMI≥25 kg/m2) and 69% of patients were clinically obese (BMI≥30 kg/m2). BMI was significantly associated with local-regional recurrence-free interval for invasive and DCIS patients (hazard ratio 1.09, p=0.047), and there was a trend for increased local-regional recurrence with higher BMI (p=0.09) for patients with invasive disease, which was significant when examining BMI above and below the median value of 33.2 (p=0.008). BMI was also significantly associated with decreased distant recurrence-free interval (DRFI; HR 1.09, p=0.011) and overall survival (OS; HR 1.09, p=0.004); this association remained on multivariate analysis (DRFI, p=0.034; overall survival, p=0.0007). Conclusions These data suggest that BMI may impact the rate of local-regional recurrence in breast cancer patients. Higher BMI predicted worse distant recurrence-free interval and overall survival. This investigation adds to growing evidence that BMI is an important prognostic factor in early stage breast cancer treated with breast conservation therapy.

show abstract

“…Multinational research shows increasing levels of obesity that are most pronounced in the Middle East including Saudi Arabia [ 8 ]. Limited local studies in Saudi Arabia confirmed obesity [body mass index (BMI) ≥ 30] in 40% of women from the general population and in more than half of those with BC [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer

Zekri

Farag

Allithy

2018

ecancer

View full text Add to dashboard Cite

IntroductionAromatase enzyme activity is predominant in adipose tissue. This has led to speculation that aromatase activity is elevated in obese women and subsequently decreased the clinical activity of adjuvant aromatase inhibitors (AIs) in women with estrogen receptor positive (ER+) breast cancer (BC). We investigated the effect of obesity on the outcome of this population.Patients and methodsRecords of 320 consecutive post-menopausal (PM) women with ER+ BC starting single agent adjuvant letrozole between years 2005 and 2014 were retrospectively reviewed. Tumour and patients characteristic including body mass index (BMI) on the day of starting letrozole were extracted. Endpoints of main interest were: (1) Frequency of obesity; (2) relapse-free survival (RFS) in nonobese (G1; BMI < 30) and obese (G2; BMI ≥ 30) patients.ResultsObesity (BMI: 30–34.99) and morbid obesity (BMI ≥ 35) were present in 105/320 (32.8%) and 115/320 (35.9%) women, respectively. Median follow-up of patients was 49 months; RFS at 5 years (G1: 69% versus G2: 78%) and at 8 years (G1: 69% versus G2: 71%). Median RFS is not reached in both groups (Log rank; P = 0.097). There was no correlation between BMI and RFS (correlation coefficient r = 0.075; P = 0.174).ConclusionIn this cohort, more than two-thirds of PM women starting adjuvant AIs are obese. Obesity did not adversely affect the outcome of women on adjuvant letrozole.

show abstract

Impact of body mass lndex on locoregional control in saudi patients with breast cancer after breast conserving surgery and modified radical mastectomy

Cited by 3 publications

References 13 publications

Impact of body mass index on survival outcome in patients with differentiated thyroid cancer

Impact of body mass index on survival outcome in patients with differentiated thyroid cancer

Association of Locoregional Control With High Body Mass Index in Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer

Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer

Contact Info

Product

Resources

About